CAJ | 학술논문

目的研究阿诺宁乳化剂的抗瘤作用和急性毒性反应.方法用小鼠和裸鼠移植性肿瘤模型测定体内抗瘤活性,用Blliss方法计算小鼠给药的急性毒性的LD50.结果阿诺宁乳化剂在4,8和16 mg*kg-1,灌胃(ig) qd×10 d,对小鼠肝癌HepS 3批实验的平均抑瘤率分别为39.2%,46.9%和55.7%;对小鼠肉瘤S-180的平均抑瘤率分别为34.6%,47.3%和54.4%;对小鼠L2的平均抑瘤率分别为37.5%,45.9%和56.5%.阿诺宁乳化剂在7.5,15,30和60 μg*kg-1腹腔注射(ip)×10d 剂量下,对小鼠肝癌(HepS)实验的平均抑瘤率分别为31.0%,42.9%,50.2%和62.4%;对小鼠肉瘤S-180的平均抑瘤率依次为23.6%,39.4%,50.9%和61.2%;在15,30和60 μg*kg-1,ip,每日1次,每周6次,共4周的剂量下,对人肝癌(Bel-7402)裸鼠移植瘤的抑瘤率分别为32.0%,50.5%和60.2%;在上述3个剂量下,对人肺腺癌(GLC-82)裸鼠移植瘤的抑瘤率分别为30.3%,41.9%和56.1%.结果表明,阿诺宁乳化剂ig,ip对上述5种肿瘤均有明显的抑制作用,且其抑瘤率与阿诺宁乳剂的剂量相关.用Bliss方法统计出阿诺宁乳化剂对小鼠ig一次的半数致死量(LD50)及其95%可信限为74.75 (58.67～5.26) mg*kg-1;ip的LD50为1.12 (1.01～1.24) mg*kg-1,静脉注射(iv)的LD50为1.81(1.61～2.03) mg*kg-1.结论阿诺宁乳化剂对多种小鼠和裸鼠移植瘤均有明显抗瘤作用.
목적연구아낙저유화제적항류작용화급성독성반응.방법용소서화라서이식성종류모형측정체내항류활성,용Blliss방법계산소서급약적급성독성적LD50.결과아낙저유화제재4,8화16 mg*kg-1,관위(ig) qd×10 d,대소서간암HepS 3비실험적평균억류솔분별위39.2%,46.9%화55.7%;대소서육류S-180적평균억류솔분별위34.6%,47.3%화54.4%;대소서L2적평균억류솔분별위37.5%,45.9%화56.5%.아낙저유화제재7.5,15,30화60 μg*kg-1복강주사(ip)×10d 제량하,대소서간암(HepS)실험적평균억류솔분별위31.0%,42.9%,50.2%화62.4%;대소서육류S-180적평균억류솔의차위23.6%,39.4%,50.9%화61.2%;재15,30화60 μg*kg-1,ip,매일1차,매주6차,공4주적제량하,대인간암(Bel-7402)라서이식류적억류솔분별위32.0%,50.5%화60.2%;재상술3개제량하,대인폐선암(GLC-82)라서이식류적억류솔분별위30.3%,41.9%화56.1%.결과표명,아낙저유화제ig,ip대상술5충종류균유명현적억제작용,차기억류솔여아낙저유제적제량상관.용Bliss방법통계출아낙저유화제대소서ig일차적반수치사량(LD50)급기95%가신한위74.75 (58.67～5.26) mg*kg-1;ip적LD50위1.12 (1.01～1.24) mg*kg-1,정맥주사(iv)적LD50위1.81(1.61～2.03) mg*kg-1.결론아낙저유화제대다충소서화라서이식류균유명현항류작용.